A PHASE II, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE-RANGING (35MG/D OR 70MG/D)

A 期、安慰剂对照、双盲、剂量范围（35MG/D 或 70MG/D）

• 批准号: 7606180
• 负责人: RONALD Sherwin SWERDLOFF
• 金额: $ 1.44万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606180
• 关键词: Acne; Adult; Adverse effects; Age; Aging; Alcohol consumption; Androgens; Area; Biological Assay; Blood; Blood Tests; Body Composition; Bone Density; Breast; Cancer Etiology; Child; Cholesterol; Cognition; Computer Retrieval of Information on Scientific Projects Database; Consent; DEXA; Daily; Development; Dose; Double-Blind Method; Electrocardiogram; End Point; Endocrine; Enrollment; Erythrocytes; Face; Female; Funding; Gel; Grant; Growth; Hair; Health; Hormones; Hypogonadism; Industry; Institution; Laboratory Research; Leg; Libido; Malignant neoplasm of prostate; Measures; Methods; Moods; Normal Range; Obstruction; PSA level; Patients; Persons; Pharmaceutical Preparations; Phase; Physiological; Placebo Control; Placebos; Pre-study; Prostate; Protective Clothing; Protocols documentation; Quality of life; Questionnaires; Randomized; Range; Reading; Replacement Therapy; Research; Research Personnel; Resources; Screening Result; Screening procedure; Serum; Sex Functioning; Skin; Source; Stanolone; Suggestion; Swelling; Symptoms; Telephone; Testing; Testosterone; Thick; Ultrasonography; United States National Institutes of Health; Urine; Visit; Walking; Weight Gain; Woman; bone; clinically significant; day; desire; diaries; erection; experience; impression; male; men; muscle strength; older men; physical process; prostate enlargement; serum PSA; size; skin irritation

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an investigator initiated, industry sponsored protocol which was conceived with significant input by the investigators at Harbor. This is a multi-center study in male subjects ages 60-80 who have low serum testosterone and symptoms of hypogonadism. There will be approximately 120 patients (40 in each treatment group). They will be given 35 mg/d, 70 mg/d dihydrotestosterone (DHT) gel, or a placebo gel. All subjects will apply the gel once daily. The primary efficacy endpoint in this study is an increase in Lean Body Mass (LBM) as determined by the DEXA (a machine used to measure bone mineral density and total body composition). Secondary endpoints in this study include changes in Libido, muscle strength, sexual function, aging male symptom scale, quality of life, normal testosterone levels, cognition, mood, and clinician's global impression of change. The study will occur over a six-month period. Before the subject is randomized to receive study medications, he will undergo a screening phase, which includes the consent process, physical exam, blood tests, urine tests, and an electrocardiogram (EKG). If all results of the screening are found to be within the normal range, the subject will be randomized to receive either 35 mg/d, 70 mg/d DHT or placebo gel. They will also undergo a prostate ultrasound, blood test, DEXA, muscle strength testing and a six-minute walk test, at the baseline visit. Subjects will return to the GCRC on months 1, 3, and 6, for blood tests (to measure hormone levels), completion of questionnaires, vital sign assessment, and assessment of gel application areas. A seven-day diary will be completed prior to each visit to record sexual desire, erections, and alcohol intake. Physical exam will be done at months 3 and 6. An prostate ultrasound will be repeated at month 6 (end of study). At months 2, 4, and 5, subjects will be telephoned to inquire about their daily gel treatment and any changes in their health and medications. The total amount of blood drawn for the study will be less than a pint. The patient may benefit from the effects of androgen replacement therapy including improvement in sexual function and an increase of lean body mass and bone thickness. The anticipated total male hormone (DHT plus testosterone) levels achieved after DHT application will be within the physiologic range of the total androgen level in adult men. It is unlikely that the subjects will experience any clinically significant side effects, except for mild weight gain, oiliness of skin, acne, and skin irritation. Other possible side effects include: increase in red blood cells, breast tenderness, leg swelling, changes in cholesterol levels, increase in prostate size and symptoms of obstruction to urine flow. There is no clear evidence that shows that male hormones cause cancer of the prostate. Men will be followed with serum PSA levels and prostate ultrasound will be done at baseline and end of study. Men with pre-study symptoms of difficulty in urinating will not be eligible to participate. Prolonged skin contact by the female partner where DHT is applied may result in some slight increase of facial hair in the partner. Patients will wear protective clothing or showered before close contact with females and children. It must be kept out of reach from women, children, and persons with inability to read and understand. As mentioned above, we anticipate screening and enrolling 120 subjects and randomizing no more than 40 subjects here at Harbor-UCLA. However, this study will be done at two other centers, besides Harbor-UCLA, and all hormone assays from the 120 subjects randomized from all three centers will be done at the GCRC or the Endocrine Research Laboratory of the investigators. This study will help develop a new transdermal method for androgen replacement for aging, hypogonadal men. Although DHT is the most abundant male hormone within the prostate, there is no evidence that administration of exogenous DHT will increase the DHT levels in the prostate. On the contrary there have been suggestions that as DHT cannot be converted to the female hormone and as both male and female hormones are required for the development of prostate enlargement in older men, DHT has been suggested to have less prostate growth promoting effect than testosterone itself.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这是一项由调查员发起、行业赞助的方案，是在 Harbor 调查员的大力投入下构思的。 这是一项针对 60-80 岁血清睾酮水平低且有性腺机能减退症状的男性受试者的多中心研究。 大约有 120 名患者（每个治疗组 40 名）。 他们将接受 35 毫克/天、70 毫克/天的二氢睾酮 (DHT) 凝胶或安慰剂凝胶。 所有受试者每天涂抹一次凝胶。 本研究的主要疗效终点是 DEXA（一种用于测量骨矿物质密度和全身成分的机器）确定的去脂体重 (LBM) 的增加。 这项研究的次要终点包括性欲、肌肉力量、性功能、衰老男性症状量表、生活质量、正常睾酮水平、认知、情绪和临床医生对变化的总体印象的变化。 该研究将持续六个月。 在受试者被随机分配接受研究药物之前，他将经历筛选阶段，包括同意过程、体检、血液检查、尿液检查和心电图 (EKG)。 如果所有筛查结果均在正常范围内，受试者将被随机分配接受 35 毫克/天、70 毫克/天 DHT 或安慰剂凝胶。 他们还将在基线访视时接受前列腺超声、血液检查、DEXA、肌肉力量测试和六分钟步行测试。 受试者将在第 1、3 和 6 个月返回 GCRC，进行血液测试（以测量激素水平）、完成问卷、生命体征评估和凝胶应用区域评估。 每次就诊前都会完成一份为期 7 天的日记，记录性欲、勃起和酒精摄入量。 体检将在第 3 个月和第 6 个月进行。前列腺超声检查将在第 6 个月（研究结束）重复进行。在第 2、4 和 5 个月，受试者将接到电话询问他们的日常凝胶治疗以及他们的健康和药物治疗的任何变化。 用于研究的抽血总量将少于一品脱。 患者可能受益于雄激素替代疗法的效果，包括改善性功能以及增加去脂体重和骨厚度。 应用 DHT 后预期达到的总雄性激素（DHT 加睾酮）水平将在成年男性总雄激素水平的生理范围内。 除了轻微的体重增加、皮肤油腻、痤疮和皮肤刺激之外，受试者不太可能出现任何临床上显着的副作用。 其他可能的副作用包括：红细胞增加、乳房压痛、腿部肿胀、胆固醇水平变化、前列腺体积增大以及尿流阻塞症状。 没有明确的证据表明雄性激素会导致前列腺癌。 将跟踪男性的血清 PSA 水平，并在基线和研究结束时进行前列腺超声检查。研究前有排尿困难症状的男性没有资格参加。 女性伴侣长时间与涂抹 DHT 的皮肤接触可能会导致伴侣面部毛发略有增加。患者在与女性和儿童密切接触之前将穿上防护服或淋浴。必须将其放在妇女、儿童和无法阅读和理解的人接触不到的地方。 如上所述，我们预计在 Harbor-UCLA 筛选和招募 120 名受试者，并随机分配不超过 40 名受试者。 然而，这项研究将在Harbor-UCLA 之外的另外两个中心进行，并且从所有三个中心随机抽取的 120 名受试者的所有激素测定都将在 GCRC 或研究人员的内分泌研究实验室进行。 这项研究将有助于开发一种新的透皮方法，用于替代衰老、性腺功能减退的男性的雄激素。尽管 DHT 是前列腺内最丰富的雄性激素，但没有证据表明施用外源性 DHT 会增加前列腺中的 DHT 水平。相反，有人建议，由于双氢睾酮不能转化为雌性激素，并且由于老年男性前列腺肥大的发展需要男性和女性激素，因此双氢睾酮被认为比睾酮本身具有更少的前列腺生长促进作用。